Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Total Current Liabilities: 2020-2024

Historic Total Current Liabilities for Biofrontera (BFRI) over the last 5 years, with Dec 2024 value amounting to $12.0 million.

  • Biofrontera's Total Current Liabilities rose 13.79% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year increase of 13.79%. This contributed to the annual value of $12.0 million for FY2024, which is 33.54% down from last year.
  • Latest data reveals that Biofrontera reported Total Current Liabilities of $12.0 million as of FY2024, which was down 33.54% from $18.1 million recorded in FY2023.
  • Over the past 5 years, Biofrontera's Total Current Liabilities peaked at $20.9 million during FY2022, and registered a low of $4.4 million during FY2020.
  • For the 3-year period, Biofrontera's Total Current Liabilities averaged around $17.0 million, with its median value being $18.1 million (2023).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 213.03% in 2021, then slumped by 33.54% in 2024.
  • Over the past 5 years, Biofrontera's Total Current Liabilities (Yearly) stood at $4.4 million in 2020, then surged by 213.03% to $13.8 million in 2021, then surged by 51.01% to $20.9 million in 2022, then fell by 13.43% to $18.1 million in 2023, then slumped by 33.54% to $12.0 million in 2024.